(DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 04 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2025, 17:02:30 UTC
Prior SEC filing: 12 Oct 2023
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam M. Veness, as attorney-in-fact for Sujay Kango

Key filing fact

Sujay Kango filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 05 Mar 2025.

Key facts

This page summarizes Sujay Kango's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2025, 17:02.

Change

Previous filing in this sequence was filed on 12 Oct 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 04 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $19.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock underlying this stock option award will vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.